Phio Pharmaceuticals (PHIO)CEO bought ~$5.1K

~$5.1K

Approx. value · 5,000 sh @ $1.02

286K

Holds after · shares reported

Traded

Dec 23, 2025

Filed

Dec 29, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 31, 2025Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On October 31, 2025, Robert Ferrara resigned, effective immediately, from his position as a director of Phio Pharmaceutical Corp.’s (the “Company’s”) Board of Directors (the “Board”), including his memberships on the Compensation Committee and the Audit Committee, and as Lead Independent Director of the Board.”
2. Nov 3, 2025Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
3. Nov 13, 2025Company filing · Form 8-K · ResultsReported its results
4. Nov 18, 2025InsiderCEO purchased ~$6.3K of PHIO shares in the open market
5. Nov 21, 2025InsiderCEO purchased ~$5.7K of PHIO shares in the open market
6. Dec 23, 2025 · this disclosureInsiderCEO purchased ~$5.1K of PHIO shares in the open market

What came next

1. Dec 31, 2025InsiderCEO purchased ~$5.2K of PHIO shares in the open market
2. Feb 17, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member
3. Mar 5, 2026Company filing · Form 8-K · ResultsReported its results
4. Apr 8, 2026Company filing · Form 8-K · Material agreementSigned an important agreement

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Phio Pharmaceuticals

For Phio Pharmaceuticals, OQRO holds 7 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PHIO page.

Other recent filings by Robert J Bitterman, Chairman, Pres. & CEO

• SEC Form 4 at Phio Pharmaceuticals (PHIO)Sep 23, 2026
• SEC Form 4 at Phio Pharmaceuticals (PHIO)Aug 19, 2026
• SEC Form 4 at Phio Pharmaceuticals (PHIO)Jun 29, 2026
• SEC Form 4 at Phio Pharmaceuticals (PHIO)Jan 2, 2026
• SEC Form 4 at Phio Pharmaceuticals (PHIO)Nov 24, 2025

The full history of Robert J Bitterman, Chairman, Pres. & CEO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Phio Pharmaceuticals

• SEC Form 4Sep 30, 2026
• SEC Form 4Sep 30, 2026
• SEC Form 4Sep 25, 2026
• SEC Form 4Sep 23, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 4Aug 20, 2026

Everything OQRO holds on this company is on its PHIO page.